CX 5461,
CX-5461,
CX5461,
CX-5461,
1138549-36-6,
CX5461,
CX 5461,
UNII-3R4C5YLB9I,
2-(4-methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide,
3R4C5YLB9I,
C27H27N7O2S,
2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo(4,5)thiazolo(3,2-a)(1,8)naphthyridine-6-carboxamide,
2-(4-methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide,
2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-5H-benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide,
cc-1,
SCHEMBL12254622,
CHEBI:95090,
DTXSID20150591,
SYN3031,
AOB87721,
BCP02547,
EX-A1303,
ABP000959,
s2684,
AKOS026750351,
ZINC100015134,
BCP9000561,
CS-0568,
RL00546,
SB17209,
CX-5461/CX5461/,
NCGC00346627-01,
NCGC00346627-08,
4CA-0419,
AK473866,
AS-16363,
BC638845,
HY-13323,
AB0035871,
Y0304,
A11065,
W-5852,
J-506426,
CX-5461,CAS:1138549-36-6,
1138549-36-6 pound not CX5461 pound not CX 5461,
2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,
2-(4-methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8],
2-(Hexahydro-4-methyl-1h-1,4-diazepin-1-yl)-n-[(5-Methyl-2-pyrazinyl)methyl]-5-oxo-5h-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carbo xamide,
4-(4-methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-8-oxo-11-thia-1,3-diazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca-2,4,6,9,12,14,16-heptaene-9-carboxamide,
D0B7LU,
XGPBJCHFROADCK-UHFFFAOYSA-N,
A8337,
RNA ppolymerase I inhibitor (oral, cancer), Cylene,